(Q37247107)

19 August 2017

A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer (English)

1 reference

19 August 2017

phase II clinical trial

0 references

author name string

Richard T Lee

1

1 reference

19 August 2017

Kathleen E Beekman

2

1 reference

19 August 2017

Maha Hussain

3

1 reference

19 August 2017

Nancy B Davis

4

1 reference

19 August 2017

Joseph I Clark

5

1 reference

19 August 2017

Sachdev P Thomas

6

1 reference

19 August 2017

Katherine F Nichols

7

1 reference

19 August 2017

Walter M Stadler

8

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 March 2008

1 reference

Clinical Genitourinary Cancer

19 August 2017

1 reference

19 August 2017

6

1 reference

19 August 2017

1

1 reference

19 August 2017

21-24

1 reference

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704464

Sorafenib in advanced clear-cell renal-cell carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704464

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704464

Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704464

The von Hippel-Lindau tumor suppressor protein influences microtubule dynamics at the cell periphery

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704464

Bevacizumab for patients with metastatic renal cancer: an update

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704464

Epothilones: mechanism of action and biologic activity

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704464

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704464

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704464

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704464

Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704464

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704464

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704464

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704464

Designs for efficient clinical trials

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704464

Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704464

Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704464

Rising incidence of renal cell cancer in the United States

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704464

Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2704464

3 September 2018

Identifiers

DOI

10.3816/CGC.2008.N.003

1 reference

19 August 2017

1 reference

19 August 2017

1 reference